Skip to content

EFFICACY OF KACA KACAA KUDINEER WITH LIFESTYLE MODIFICATIONS IN CHRONIC INSOMNIA AMONG IT PROFESSIONALS

PREVALENCE AND EFFICACY OF KACA KACAA KUDINEER WITH LIFESTYLE MODIFICATIONS IN CHRONIC INSOMNIA AMONG IT PROFESSIONALS- AN INTERVENTIONAL STUDY

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024254
Enrollment
40
Registered
2020-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia

Interventions

Intervention1: kaca kacaa kudineer: 60 ml of kaca kacaa kudineer at bedtime for 21 days Control Intervention1: Lifestyle modifications: 60 ml of Kaca kacaa kudineer at bedtime for 21 days with lifesty

Sponsors

Government siddha medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and female aged 25 ââ?¬â?? 40 years. Insomnia Severity Index score >15.

Exclusion criteria

Exclusion criteria: ïÆ?Ë? Untreated cardiovascular disease, arrhythmias (other than well controlled atrial fibrillation), hypertension or severe heart failure ïÆ?Ë? History of allergies particularly to plant-based products containing terpenes, I.e. flavours and aromatic natural oils for example citrus, mango, lavender, thyme, cedarwood and pine products ïÆ?Ë? Currently regularly using (greater than or equal to 3 nights/days per week) psychotropic or CNS-active drugs (including cannabis, opioids, benzodiazepines) ïÆ?Ë? Inability to refrain from use of psychotropic or CNS-active drugs (including cannabis, opioids, benzodiazepines) for at least one week prior to and duration of study ïÆ?Ë? Inability to refrain from use of Cytochrome P450 inhibitors for at least one week prior to and duration of study. Examples include macrolide antibiotics (erythromycin, clarithromycin), azole antifungals (itraconazole, ketoconazole, posaconazole, voriconazole), protease inhibitors (ritonavir, telaprevir, boceprevir), calcium channel blockers (amlopdipine), high cholesterol medication (gemfibrozil), cyclosporine, danazol, tachycardia medication (amiodarone), hypertension medication (verapamil, diltiazem), niacin (vitamin B3 greater than 1g/ day), grapefruit juice ïÆ?Ë? Untreated metabolic disorders such as diabetes ïÆ?Ë? Presence of severe depression, severe anxiety or other severe psychopathologic conditions. ïÆ?Ë? History of suicide attempt or current suicide ideation. ïÆ?Ë? History of seizures or epilepsy ïÆ?Ë? History of drug or alcohol abuse ïÆ?Ë? Insomnia associated with sleep apnea ïÆ?Ë? Are currently participating in a formal behavioural therapy program to facilitate sleep ïÆ?Ë? Pregnancy or lactation ïÆ?Ë? Inability to refrain from greater than 2 standard drinks/day of alcohol consumption for study duration ïÆ?Ë? Inability to refrain from greater than 400mg/day of caffeine consumption for study duration ïÆ?Ë? Any person required to drive within 10 hours of dose, or those with a self-reported history of falling asleep while driving ïÆ?Ë? Current delayed sleep phase syndrome where wake up time is regularly later than 8.00am.

Design outcomes

Primary

MeasureTime frame
Outcome is mainly assessed by reduction in clinical symptoms measured by Insomnia severity indexTimepoint: 6 months

Secondary

MeasureTime frame
To determine the prevalence of chronic insomnia among it professionalsTimepoint: 6 months

Countries

India

Contacts

Public ContactDr Nikil Niva J

government siddha medical college

sasirekha.siddha@gmail.com9444832728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026